Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

An efficient cell selection method is crucial to delivering a consistent autologous therapy product when the starting material received from severely ill patients is highly variable. While a variety of technologies are being adopted in the industry, there are very few GMP options, and many lack the flexibility for multiple passes, and flexibility in reagent selection. In addition, the currently available technologies are often applied in combination with manufacturing platforms that are manual, semi-automated and lacking commercial viability.

During this webinar, our experts will share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, we will learn about transitioning manual cell therapy production to automated processes that are scalable to meet clinical and commercial demands.

• Background, and the current status, of the Malaghan Institute’s CD19 cell therapy in a Phase I clinical trial
• Translation of Malaghan's open, manual manufacturing process into a fully automated workflow from sample loading, cell selection to harvest
• Magnetic selection in the Cocoon^® Platform and results

Kenneth Olsen PhD

Senior R&D Scientist, Personalized Medicine Business Unit, Lonza

Rachel Perret PhD

Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research

Dr. Rachel Perret is a Senior Cancer Research Fellow and Team Leader of the CAR T-cell Research Programme at New Zealand’s Malaghan Institute of Medical Research. She studied Microbiology at the University of Otago, NZ, before undertaking her PhD in Immunology with Professor Franca Ronchese at the Malaghan Institute. Rachel spent several years overseas, first at the Lausanne Branch of the Ludwig Institute for Cancer Research, and then at the Fred Hutchinson Cancer Research Center, and returned to the Malaghan Institute in January 2020. Her research focus lies in investigating chimeric antigen receptor (CAR) T-cell signalling and function, in order to design even better, safer, and more broadly applicable CAR T-cell therapies for cancer

Watch now

SPEAKERS

Kenneth Olsen PhD

Senior R&D Scientist, Personalized Medicine Business Unit, Lonza

Rachel Perret PhD

Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research

You might also like

Expediting development and manufacture of advanced therapies: critical starting materials case study

Andrew Frazer

21 February

Watch

iPSC cell line development and manufacture for cell therapies

R Flynn, B Ressler, D Hei et al.

14 March

Watch

Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?

S Werner, S Curbishley, J Jendusa

10 April

Watch

Preserving the future of medicine: standardizing leukapheresis materials with cryopreservation for scalable cell therapies

R Luke, M Giedlin, D Clarke et al.

12 December

in 19

Days

Register

Enhancing CAR-T therapy development: harnessing cell selection flexibility

Tamara Laskowski, Nuala Trainor

2 October

Watch